Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Type I and type III interferons differ in their adjuvant activities for influenza vaccines.

Ye L, Ohnemus A, Ong LC, Gad HH, Hartmann R, Lycke N, Staeheli P.

J Virol. 2019 Sep 11. pii: JVI.01262-19. doi: 10.1128/JVI.01262-19. [Epub ahead of print]

PMID:
31511392
2.

Class-switch recombination to IgA in the Peyer's patches requires natural thymus-derived Tregs and appears to be antigen independent.

Gribonika I, Eliasson DG, Chandode RK, Schön K, Strömberg A, Bemark M, Lycke NY.

Mucosal Immunol. 2019 Sep 9. doi: 10.1038/s41385-019-0202-0. [Epub ahead of print]

PMID:
31501516
3.

Gel Phase 1,2-Distearoyl-sn-glycero-3-phosphocholine-Based Liposomes Are Superior to Fluid Phase Liposomes at Augmenting Both Antigen Presentation on Major Histocompatibility Complex Class II and Costimulatory Molecule Display by Dendritic Cells in Vitro.

Norling K, Bernasconi V, Agmo Hernández V, Parveen N, Edwards K, Lycke NY, Höök F, Bally M.

ACS Infect Dis. 2019 Sep 24. doi: 10.1021/acsinfecdis.9b00189. [Epub ahead of print]

PMID:
31498993
4.

Activated Peyer's patch B cells sample antigen directly from M cells in the subepithelial dome.

Komban RJ, Strömberg A, Biram A, Cervin J, Lebrero-Fernández C, Mabbott N, Yrlid U, Shulman Z, Bemark M, Lycke N.

Nat Commun. 2019 Jun 3;10(1):2423. doi: 10.1038/s41467-019-10144-w.

5.

Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.

Bhide Y, Dong W, Gribonika I, Voshart D, Meijerhof T, de Vries-Idema J, Norley S, Guilfoyle K, Skeldon S, Engelhardt OG, Boon L, Christensen D, Lycke N, Huckriede A.

Front Immunol. 2019 Mar 29;10:646. doi: 10.3389/fimmu.2019.00646. eCollection 2019.

6.

Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin.

Ye L, Schnepf D, Becker J, Ebert K, Tanriver Y, Bernasconi V, Gad HH, Hartmann R, Lycke N, Staeheli P.

Nat Immunol. 2019 May;20(5):593-601. doi: 10.1038/s41590-019-0345-x. Epub 2019 Mar 18.

PMID:
30886417
7.

Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.

Bernasconi V, Bernocchi B, Ye L, Lê MQ, Omokanye A, Carpentier R, Schön K, Saelens X, Staeheli P, Betbeder D, Lycke N.

Front Immunol. 2018 Sep 12;9:2060. doi: 10.3389/fimmu.2018.02060. eCollection 2018.

8.

ADP-ribosylating enterotoxins as vaccine adjuvants.

Lycke N, Lebrero-Fernández C.

Curr Opin Pharmacol. 2018 Aug;41:42-51. doi: 10.1016/j.coph.2018.03.015. Epub 2018 May 22. Review.

PMID:
29702466
9.

Targeting Mycobacterium tuberculosis Antigens to Dendritic Cells via the DC-Specific-ICAM3-Grabbing-Nonintegrin Receptor Induces Strong T-Helper 1 Immune Responses.

Velasquez LN, Stüve P, Gentilini MV, Swallow M, Bartel J, Lycke NY, Barkan D, Martina M, Lujan HD, Kalay H, van Kooyk Y, Sparwasser TD, Berod L.

Front Immunol. 2018 Mar 9;9:471. doi: 10.3389/fimmu.2018.00471. eCollection 2018.

10.

A Sensitive Method for Detecting Peptide-specific CD4+ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis.

Sharma S, Malmeström C, Lindberg C, Meisel S, Schön K, Verolin M, Lycke NY.

Front Immunol. 2017 Oct 24;8:1370. doi: 10.3389/fimmu.2017.01370. eCollection 2017.

11.

A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.

Consonni A, Sharma S, Schön K, Lebrero-Fernández C, Rinaldi E, Lycke NY, Baggi F.

Front Immunol. 2017 Sep 13;8:1133. doi: 10.3389/fimmu.2017.01133. eCollection 2017.

12.

The regulation of gut mucosal IgA B-cell responses: recent developments.

Lycke NY, Bemark M.

Mucosal Immunol. 2017 Nov;10(6):1361-1374. doi: 10.1038/mi.2017.62. Epub 2017 Jul 26. Review.

PMID:
28745325
13.

Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology.

O'Meara CP, Armitage CW, Andrew DW, Kollipara A, Lycke NY, Potter AA, Gerdts V, Petrovsky N, Beagley KW.

Vaccine. 2017 Jul 5;35(31):3883-3888. doi: 10.1016/j.vaccine.2017.05.063. Epub 2017 Jun 8.

PMID:
28602608
14.

M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, Kolpe A, El Bakkouri K, Ysenbaert T, Deng L, Fiers W, Saelens X, Lycke N.

Mucosal Immunol. 2018 Jan;11(1):273-289. doi: 10.1038/mi.2017.14. Epub 2017 Mar 1.

PMID:
28295019
15.

Per Brandtzaeg: patron of mucosal immunology.

Sollid LM, Lycke N.

Mucosal Immunol. 2017 Jan;10(1):1-4. doi: 10.1038/mi.2016.111. No abstract available.

PMID:
28138161
16.

Mucosal Vaccine Development Based on Liposome Technology.

Bernasconi V, Norling K, Bally M, Höök F, Lycke NY.

J Immunol Res. 2016;2016:5482087. doi: 10.1155/2016/5482087. Epub 2016 Dec 29. Review.

17.

Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.

Hadad R, Marks E, Kalbina I, Schön K, Unemo M, Lycke N, Strid Å, Andersson S.

APMIS. 2016 Dec;124(12):1078-1086. doi: 10.1111/apm.12605.

PMID:
27859689
18.

Limited clonal relatedness between gut IgA plasma cells and memory B cells after oral immunization.

Bemark M, Hazanov H, Strömberg A, Komban R, Holmqvist J, Köster S, Mattsson J, Sikora P, Mehr R, Lycke NY.

Nat Commun. 2016 Sep 6;7:12698. doi: 10.1038/ncomms12698.

19.

Feeding transgenic plants that express a tolerogenic fusion protein effectively protects against arthritis.

Hansson C, Schön K, Kalbina I, Strid Å, Andersson S, Bokarewa MI, Lycke NY.

Plant Biotechnol J. 2016 Apr;14(4):1106-15. doi: 10.1111/pbi.12479. Epub 2015 Sep 25.

20.

Cutting Edge: Retinoic Acid Signaling in B Cells Is Essential for Oral Immunization and Microflora Composition.

Pantazi E, Marks E, Stolarczyk E, Lycke N, Noelle RJ, Elgueta R.

J Immunol. 2015 Aug 15;195(4):1368-71. doi: 10.4049/jimmunol.1500989. Epub 2015 Jul 10.

21.

ELISPOT Assay for Measurement of Antigen-Specific and Polyclonal Antibody Responses.

Lycke N, Coico R.

Curr Protoc Immunol. 2015 Feb 2;108:7.14.1-10. doi: 10.1002/0471142735.im0714s108.

PMID:
25640992
22.

Cholera toxin adjuvant promotes a balanced Th1/Th2/Th17 response independently of IL-12 and IL-17 by acting on Gsα in CD11b⁺ DCs.

Mattsson J, Schön K, Ekman L, Fahlén-Yrlid L, Yrlid U, Lycke NY.

Mucosal Immunol. 2015 Jul;8(4):815-27. doi: 10.1038/mi.2014.111. Epub 2014 Nov 26.

PMID:
25425266
23.

Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model.

Kap YS, van Driel N, Arends R, Rouwendal G, Verolin M, Blezer E, Lycke N, 't Hart BA.

Clin Exp Immunol. 2015 Apr;180(1):28-39. doi: 10.1111/cei.12487.

24.

Antibiotic-killed Staphylococcus aureus induces destructive arthritis in mice.

Ali A, Zhu X, Kwiecinski J, Gjertsson I, Lindholm C, Iwakura Y, Wang X, Lycke N, Josefsson E, Pullerits R, Jin T.

Arthritis Rheumatol. 2015 Jan;67(1):107-16. doi: 10.1002/art.38902.

25.

The 18th Germinal Centre Meeting.

Lycke N, Mårtensson-Bopp L, Yrlid U, Bemark M.

Scand J Immunol. 2014 Sep;80(3):159-60. doi: 10.1111/sji.12219. No abstract available.

26.

Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.

Nedrud JG, Bagheri N, Schön K, Xin W, Bergroth H, Eliasson DG, Lycke NY.

PLoS One. 2013 Dec 31;8(12):e83321. doi: 10.1371/journal.pone.0083321. eCollection 2013.

27.

Immunity against a Chlamydia infection and disease may be determined by a balance of IL-17 signaling.

O'Meara CP, Armitage CW, Harvie MC, Andrew DW, Timms P, Lycke NY, Beagley KW.

Immunol Cell Biol. 2014 Mar;92(3):287-97. doi: 10.1038/icb.2013.92. Epub 2013 Dec 24.

PMID:
24366518
28.

IgA B Cell Responses to Gut Mucosal Antigens: Do We Know it all?

Lycke NY.

Front Immunol. 2013 Nov 13;4:368. doi: 10.3389/fimmu.2013.00368. eCollection 2013. No abstract available.

29.

Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.

O'Meara CP, Armitage CW, Harvie MC, Timms P, Lycke NY, Beagley KW.

PLoS One. 2013 Apr 16;8(4):e61962. doi: 10.1371/journal.pone.0061962. Print 2013.

30.

The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization.

Fang Y, Zhang T, Lidell L, Xu X, Lycke N, Xiang Z.

Mucosal Immunol. 2013 Nov;6(6):1168-78. doi: 10.1038/mi.2013.16. Epub 2013 Apr 10.

PMID:
23571505
31.

The role of Peyer's patches in synchronizing gut IgA responses.

Lycke NY, Bemark M.

Front Immunol. 2012 Nov 7;3:329. doi: 10.3389/fimmu.2012.00329. eCollection 2012.

32.

Recent progress in mucosal vaccine development: potential and limitations.

Lycke N.

Nat Rev Immunol. 2012 Jul 25;12(8):592-605. doi: 10.1038/nri3251. Review.

PMID:
22828912
33.

Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses.

Bergqvist P, Stensson A, Hazanov L, Holmberg A, Mattsson J, Mehr R, Bemark M, Lycke NY.

Mucosal Immunol. 2013 Jan;6(1):122-35. doi: 10.1038/mi.2012.56. Epub 2012 Jul 11.

PMID:
22785230
34.

Induction of gut IgA production through T cell-dependent and T cell-independent pathways.

Bemark M, Boysen P, Lycke NY.

Ann N Y Acad Sci. 2012 Jan;1247:97-116. doi: 10.1111/j.1749-6632.2011.06378.x. Epub 2012 Jan 19. Review.

PMID:
22260403
35.

Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant.

Mattsson J, Yrlid U, Stensson A, Schön K, Karlsson MC, Ravetch JV, Lycke NY.

J Immunol. 2011 Oct 1;187(7):3641-52. doi: 10.4049/jimmunol.1101107. Epub 2011 Aug 31.

36.

CD4⁺ T-cell immunity in the female genital tract is critically dependent on local mucosal immunization.

Marks E, Helgeby A, Andersson JO, Schön K, Lycke NY.

Eur J Immunol. 2011 Sep;41(9):2642-53. doi: 10.1002/eji.201041297.

37.

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.

Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.

Vaccine. 2011 May 23;29(23):3951-61. doi: 10.1016/j.vaccine.2011.03.090. Epub 2011 Apr 8.

PMID:
21481325
38.

A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development.

Bemark M, Bergqvist P, Stensson A, Holmberg A, Mattsson J, Lycke NY.

J Immunol. 2011 Feb 1;186(3):1399-410. doi: 10.4049/jimmunol.1002881. Epub 2011 Jan 3. Erratum in: J Immunol. 2011 Aug 1;187(3): 1517.

39.

Is the choice of vaccine adjuvant critical for long-term memory development?

Lycke N.

Expert Rev Vaccines. 2010 Dec;9(12):1357-61. doi: 10.1586/erv.10.136. No abstract available.

PMID:
21105771
40.
41.

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.

Lycke N, Bemark M.

Mucosal Immunol. 2010 Nov;3(6):556-66. doi: 10.1038/mi.2010.54. Epub 2010 Sep 15. Review.

PMID:
20844480
42.

Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.

Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.

J Immunol. 2010 Sep 1;185(5):2935-41. doi: 10.4049/jimmunol.1000589. Epub 2010 Jul 30.

43.

Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant.

Sjöblom-Hallén A, Marklund U, Nerstedt A, Schön K, Ekman L, Bergqvist P, Löwenadler B, Lycke NY.

Mucosal Immunol. 2010 Jul;3(4):374-86. doi: 10.1038/mi.2010.16. Epub 2010 Apr 7.

PMID:
20375997
44.

T cell-independent IgA class switch recombination is restricted to the GALT and occurs prior to manifest germinal center formation.

Bergqvist P, Stensson A, Lycke NY, Bemark M.

J Immunol. 2010 Apr 1;184(7):3545-53. doi: 10.4049/jimmunol.0901895. Epub 2010 Mar 5.

45.

ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization.

Hasselberg A, Ekman L, Yrlid LF, Schön K, Lycke NY.

J Immunol. 2010 Mar 15;184(6):2776-84. doi: 10.4049/jimmunol.0901445. Epub 2010 Feb 8.

46.

CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.

Cunningham KA, Carey AJ, Lycke N, Timms P, Beagley KW.

J Reprod Immunol. 2009 Jul;81(1):34-8. doi: 10.1016/j.jri.2009.04.002. Epub 2009 Jun 6.

PMID:
19501917
47.

Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis.

Hasselberg A, Schön K, Tarkowski A, Lycke N.

Arthritis Rheum. 2009 Jun;60(6):1672-82. doi: 10.1002/art.24566.

48.

CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.

Sundling C, Schön K, Mörner A, Forsell MN, Wyatt RT, Thorstensson R, Karlsson Hedestam GB, Lycke NY.

J Gen Virol. 2008 Dec;89(Pt 12):2954-64. doi: 10.1099/vir.0.2008/005470-0.

PMID:
19008380
49.

Measurement of immunoglobulin synthesis using the ELISPOT assay.

Lycke NY, Coico R.

Curr Protoc Immunol. 2001 May;Chapter 7:Unit 7.14. doi: 10.1002/0471142735.im0714s17.

PMID:
18432828
50.

Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells.

Lefrançois L, Lycke N.

Curr Protoc Immunol. 2001 May;Chapter 3:Unit 3.19. doi: 10.1002/0471142735.im0319s17.

PMID:
18432783

Supplemental Content

Support Center